The biotech sector is beginning to see a comeback after suffering a decline due to drug pricing issues raised during the U.S. Presidential election. However, the sector has gained 10.3 % in 2017, outperforming the S&P 500, which is up 6.3% YTD. A more pro-business administration, a faster drug approval process and the removal of outdated regulations that drive up costs and slow innovation are expected to benefit the biotech sector moving forward.
A very important strategy in biotech is investing at the right time and in the right companies. One segment of the biotech sector that could be ripe for investment is electroceuticals/bioelectronics, which are medical devices that use electrical, electromagnetic, mechanical or light stimulation to affect electrical signaling in tissues.
A prime example of the kind of gains that can be realized in this segment of the sector is Pulse Biosciences (PLSE), which has seen its share price nearly quadruple since February on news that healthcare executives and entrepreneurs Robert Duggan and Dr. Maky Zanganeh had acquired a combined interest of 17.1% and the recent submission by the company of its FDA 510(k) application for its PulseTx™ System. PLSE’s technology, Nano-Pulse Stimulation (NPS) uses nano second electric pulses to illicit an immune response for the treatment of cancer.
Another biotech that seems to be following the same trajectory as PLSE is Endonovo Therapeutics (ENDV), which uses Time Varying Electromagnetic Pulses to illicit an anti-inflammatory response to treat inflammatory and vascular diseases. In situations like cancer, where the immune response is too low, technologies like PLSE’s Nano-Pulse Stimulation, which illicit an immune response to treat cancer may be the future. Whereas, in situations where the immune response is too strong, such as sepsis or following ischemia/reperfusion injury, ENDV’s technology may be the future treatment modality.
On March 23rd, ENDV announced it had filed a non-provisional patent with the United States and Trademark Office (USPTO) on a method to treat tissues and organs using its Immunotronics™ technology. With a non-provisional patent application filed, you will want to keep your eye on ENDV as they progress on a method to treat tissues and organs using its non-invasive electroceutical technology.
“We are very excited about our new generation of non-invasive electroceuticals developed specifically to target vascular diseases and ischemic injuries,” stated ENDV Chairman and CEO, Alan Collier.
The Company is evaluating the therapeutic potential of its new electroceutical technology in treatment and prevention of heart failure following myocardial infarction. ENDV anticipates initial results from its ongoing pre-clinical study in the second quarter of 2017.
Furthermore, like PLSE, Endonovo Therapeutics has attracted the attention and investment of a strategic healthcare investor to finance the development of its pipeline targeting vascular diseases and ischemia/reperfusion injuries and uplist its common stock onto a national stock exchange.
IN OTHER BIOTECH NEWS…
Cerulean Pharma (CERU), the Waltham-based cancer drug developer announced last week plans to lay off half of its remaining employees and implement a reverse merger with a privately-held San Diego biotech company.
During Q1 of 2017, Athersys, Inc. (ATHX) announced a public offering that will see it distribute just shy of 20 million shares at $1.01 a share. Gross proceeds are expected to be around $20 million, meaning the company should net around $18 million on the raise. But Athersys took a hit on the release.
Shares of Pacific Biosciences of California (PACB), an as-yet-unprofitable purveyor of genome sequencing systems, jumped 14.8% as of 12:17 p.m. EDT during Wednesday’s session. It seems investor confidence is returning despite the loss of a major contract with Roche late last year.
Imprimis Pharmaceuticals, Inc. (IMMY) is engaged in the development, production and dispensing of compounded pharmaceuticals. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment.
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC. which owns Microcapspeculators.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC. which owns, Microcapspeculators.com may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC. which owns Microcapspeculators.com may be compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two.
For Full Legal Disclaimer Click Here.
Company Name: Microcap Speculators
Contact Person: Media Manager
Email: [email protected]
Country: United States